JP2013536179A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536179A5
JP2013536179A5 JP2013521954A JP2013521954A JP2013536179A5 JP 2013536179 A5 JP2013536179 A5 JP 2013536179A5 JP 2013521954 A JP2013521954 A JP 2013521954A JP 2013521954 A JP2013521954 A JP 2013521954A JP 2013536179 A5 JP2013536179 A5 JP 2013536179A5
Authority
JP
Japan
Prior art keywords
ylamino
benzo
oxazol
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013521954A
Other languages
English (en)
Japanese (ja)
Other versions
JP6073221B2 (ja
JP2013536179A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/045609 external-priority patent/WO2012015972A1/en
Publication of JP2013536179A publication Critical patent/JP2013536179A/ja
Publication of JP2013536179A5 publication Critical patent/JP2013536179A5/ja
Application granted granted Critical
Publication of JP6073221B2 publication Critical patent/JP6073221B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013521954A 2010-07-28 2011-07-27 Jak経路の阻害のための組成物および方法 Expired - Fee Related JP6073221B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36857010P 2010-07-28 2010-07-28
US61/368,570 2010-07-28
PCT/US2011/045609 WO2012015972A1 (en) 2010-07-28 2011-07-27 Compositions and methods for inhibition of the jak pathway

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016221423A Division JP2017061518A (ja) 2010-07-28 2016-11-14 Jak経路の阻害のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013536179A JP2013536179A (ja) 2013-09-19
JP2013536179A5 true JP2013536179A5 (https=) 2014-09-11
JP6073221B2 JP6073221B2 (ja) 2017-02-01

Family

ID=44504225

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013521954A Expired - Fee Related JP6073221B2 (ja) 2010-07-28 2011-07-27 Jak経路の阻害のための組成物および方法
JP2016221423A Withdrawn JP2017061518A (ja) 2010-07-28 2016-11-14 Jak経路の阻害のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016221423A Withdrawn JP2017061518A (ja) 2010-07-28 2016-11-14 Jak経路の阻害のための組成物および方法

Country Status (20)

Country Link
US (8) US8343954B2 (https=)
EP (1) EP2598500B1 (https=)
JP (2) JP6073221B2 (https=)
KR (1) KR101937495B1 (https=)
CN (1) CN103201280B (https=)
AR (2) AR082408A1 (https=)
AU (1) AU2011282742B2 (https=)
BR (1) BR112013001632B1 (https=)
CA (1) CA2804199C (https=)
DK (1) DK2598500T3 (https=)
EA (1) EA201390015A1 (https=)
ES (1) ES2880622T3 (https=)
IL (1) IL223855A (https=)
MX (2) MX347331B (https=)
PL (1) PL2598500T3 (https=)
PT (1) PT2598500T (https=)
RU (1) RU2672100C2 (https=)
TW (1) TWI582090B (https=)
WO (1) WO2012015972A1 (https=)
ZA (1) ZA201300388B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI1006942A2 (pt) 2009-01-23 2016-04-12 Rigel Pharmaceuticals Inc composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
JP6073221B2 (ja) 2010-07-28 2017-02-01 ライジェル ファーマシューティカルズ, インコーポレイテッド Jak経路の阻害のための組成物および方法
ES2658395T3 (es) 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
WO2013173506A2 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
JP2016506930A (ja) * 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ, インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
CA2904610A1 (en) 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US20160159774A1 (en) * 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
US20190060311A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
EP3707138B1 (en) * 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US20210198248A1 (en) * 2018-05-24 2021-07-01 Astrazeneca Ab Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3h)-one
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110078633B (zh) * 2019-05-24 2021-05-11 爱斯特(成都)生物制药股份有限公司 一种4-氟-3-甲氧基-5-甲基苯胺盐酸盐制备方法
WO2021239133A1 (zh) * 2020-05-29 2021-12-02 南京正大天晴制药有限公司 作为axl抑制剂的嘧啶类化合物
WO2025080099A1 (ko) * 2023-10-13 2025-04-17 주식회사유한양행 7,7-다이메틸푸로[3,4-b]피리딘-5(7h)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
WO2025109026A1 (en) * 2023-11-21 2025-05-30 Intervet International B.V. Process for the preparation of 4-fluoro-3-methoxyaniline

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
DE69228827T2 (de) 1991-12-18 1999-10-21 Minnesota Mining And Mfg. Co., Saint Paul Mehrschichtige sperrstrukturen
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
CN101282945A (zh) * 2005-06-08 2008-10-08 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8393954B2 (en) 2006-12-29 2013-03-12 Cfph, Llc Top performers
US8456526B2 (en) * 2006-08-25 2013-06-04 Sportvision, Inc. Video effect using movement within an image
WO2008118822A1 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2009063240A1 (en) * 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
BRPI1006942A2 (pt) * 2009-01-23 2016-04-12 Rigel Pharmaceuticals Inc composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
JP6073221B2 (ja) * 2010-07-28 2017-02-01 ライジェル ファーマシューティカルズ, インコーポレイテッド Jak経路の阻害のための組成物および方法
US8637038B2 (en) * 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection

Similar Documents

Publication Publication Date Title
JP2013536179A5 (https=)
RU2015122016A (ru) Композиции и способы ингибирования пути jak
US11306088B2 (en) CXCR4 inhibitors and uses thereof
ES2622493T3 (es) Composiciones y métodos para la inhibición de la ruta de JAK
JP6553632B2 (ja) Betブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
KR20220042429A (ko) Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
EP3071205A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
JP2019533687A5 (https=)
RU2008122070A (ru) Аминопиридины, используемые в качестве ингибиторов киназ
JP2019510025A (ja) ピリミジンおよびそのバリアント、ならびにそのための使用
US12053459B2 (en) CDK2 inhibitors and methods of using the same
JP2025531867A (ja) ヘテロ二官能性化合物及び疾患の治療方法
WO2024054955A1 (en) Heterobifunctional compounds and methods of treating disease
TW202613107A (zh) 化合物及其用途
WO2024264070A2 (en) Akt inhibitors
HK1185616B (en) Compositions and methods for inhibition of the jak pathway